|9 Months Ended|
Sep. 30, 2023
|Goodwill and Intangible Assets Disclosure [Abstract]|
|Intangible Assets||Intangible Assets
Intangible assets as of September 30, 2023 and December 31, 2022 consist of the following (in $000’s):
*The Soin intangibles acquired by the Company consist of the following:
1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense from continuing operations was $363,000 and $0 for the 13 weeks ended September 30, 2023 and October 1, 2022 and $1.1 million and $0 for the 39 weeks ended September 30, 2023 and October 1, 2022.
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef